EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy

Lu-Qi Cao, Haidong Sun, Yuhao Xie, Harsh Patel, Letao Bo, Hanli Lin, Zhe-Sheng Chen

Frontiers in Pharmacology · 24.01.2024 · 15

DOI: 10.3389/fphar.2024.1340764 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 24.01.2024. Verfasst von Lu-Qi Cao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biotechnology, St. John's University, Queens, NY, United States. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer, a complex and varied disease, has four distinct subtypes based on estrogen receptor and human epidermal growth factor receptor 2 (HER2) levels, among which a significant subtype known as HR+/HER2-breast cancer that has spurred numerous research. The prevalence of breast cancer and breast cancer-related death are the most serious threats to women’s health worldwide. Current progress in treatment strategies for HR+/HER2-breast cancer encompasses targeted therapy, endocrine therapy, genomic immunotherapy, and supplementing traditional methods like surgical resection and radiotherapy. This review article summarizes the current epidemiology of HR+/HER2-breast cancer, introduces the classification of HR+/HER2-breast cancer and the commonly used treatment methods. The mechanisms of action of various drugs, including targeted therapy drugs and endocrine hormone therapy drugs, and their potential synergistic effects are deeply discussed. In addition, clinical trials of these drugs that have been completed or are still in progress are included.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorHR+/HER2-breast cancerPI3K inhibitorSERDSERMclinical trial

Autor:innen und Institutionen

  • Institute for Biotechnology, St. John's University, Queens, NY, United States.
  • Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY, United States.
  • Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.

Zitieren

APA

Cao, L. Q., Sun, H., Xie, Y., Patel, H., Bo, L., Lin, H., & Chen, Z. S. (2024). Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1340764

Vancouver

Cao LQ, Sun H, Xie Y, Patel H, Bo L, Lin H, et al. Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1340764

BibTeX
@article{Cao2024,
  author = {Cao, Lu-Qi and Sun, Haidong and Xie, Yuhao and Patel, Harsh and Bo, Letao and Lin, Hanli and Chen, Zhe-Sheng},
  title = {Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1340764}
}
Kostenlos starten →